No products in the cart.
Pre-made Pavurutamab benchmark antibody ( Bispecific scFv, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-433
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of multiple myeloma.
| Products Name (INN Index) | Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Pavurutamab |
| Target | TNFRSF17,CD3E |
| Format | Bispecific scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Amgen |
| Conditions Approved | NA |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | NA |
| Development Tech | BiTE Technology |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF17,CD3E |
| Package |
Previous slide
Next slide
